Transdermal Delivery Market Predicted to Reach $31.5 Billion by 2015: PharmaLive Special Report
NEWTOWN, Pa., Sept. 7, 2011 - The transdermal delivery market was valued at $21.5 billion in 2010 and is predicted to reach $31.5 billion by 2015. The annual U.S. market for transdermal patches is estimated at more than $3 billion. Transdermal drugs account for more than 12% of the global drug delivery market.
Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes. Major advantages provided by transdermal drug delivery include improved bioavailability, more uniform plasma levels, longer duration of action resulting in less dosing frequency, reduced side effects, and improved therapy due to maintenance of plasma levels.
Transdermal drug delivery is used in areas such as pain management and women's health. Pharmaceutical, biotechnology, and drug delivery companies are poised to tap the hidden potential in transdermal drug delivery applications such as wound care, monitoring, and diagnostic methods. The development of successful transdermal drug delivery systems in these areas will play an important role in improving the quality of life.
Yaupon Therapeutics Inc., a privately held specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early-stage mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved for marketing, Yaupon's investigational drug would be the first topical mechlorethamine gel widely available to treat the signs and symptoms of this rare cancer.
The FDA has accepted NuPathe Inc.'s New Drug Application (NDA) for Zeltrix, the first submission to FDA of a transdermal patch to treat migraines. Zeltrix is an active, single-use, transdermal sumatriptan patch intended for the treatment of migraines. This patch is designed to provide patients fast onset and sustained relief through a tolerable, non-oral route of administration.
Zeltrix is powered by SmartRelief, NuPathe's proprietary transdermal delivery technology. SmartRelief consists of controlled delivery technology that uses a mild electrical current to actively transport medication through the skin via a process called iontophoresis.
More information on the outlook for this market, new technologies, and segment leaders is available in Transdermal Medicine Review and Outlook 2011, located at www.pharmalive.com/specialreports.
For additional information, contact Sandra Baker at +1-215-944-9836 or Sandra.Baker@ubm.com.
About UBM Canon Data Products
UBM Canon Data Products provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries through PharmaLive Special Reports and Appliance Market Research Reports; maintains eKnowledgeBase and MDRWeb, comprehensive market intelligence tools serving the pharmaceutical, biotechnology, and medical-device sectors; and manages company-wide Site Licenses for PharmaLive.com, Med Ad News, and R&D Directions.
About UBM Canon
UBM Canon is a business-to-business media company serving the worldwide advanced manufacturing sector through its publications, trade events, and electronic media.
Posted: September 2011